# Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)

> **NCT00408863** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 3148 (actual)

## Conditions studied

- Breast Cancer
- Climacteric Symptoms

## Interventions

- **DRUG:** tibolone
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00408863
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 3148 (ACTUAL)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408863, "Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00408863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*